

Curriculum Vitae

Personal information **Ioana Agache**

Work experience

1. Employer: Transylvania University Brasov
 - Start date: 092018
 - End date: NA
 - Position: Professor
 - Activities: Responsible for Allergy and Immunology curricula Responsible for Physiology curricula
 - Country: Romania

Education and training

1. Subject: Carol Davila University
 - Start date: 091988
 - End date: 061994
 - Qualification: Medical doctor
 - Organisation: Allergy, asthma, clinical immunology
 - Country: Romania

Additional information

Publications

Agache I, et al. EAAACI guidelines on environmental science for allergy and asthma: The impact of short-term exposure to outdoor air pollutants on asthma-related outcomes and recommendations for mitigation measures. *Allergy*. 2024;79(7):1656-1686; Agache I, et al. Immune-mediated disease caused by climate change-associated environmental hazards: mitigation and adaptation. *Front Sci*. 2024; 2:1279192; Agache I, et al. The impact of exposure to tobacco smoke and e-cigarettes on asthma-related outcomes: Systematic review informing the EAAACI guidelines on environmental science for allergic diseases and asthma. *Allergy*. 2024;79(9):2346-2365; Jutel M, Agache I, et al. Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAAACI position paper. *Allergy*. 2023;78(11):2851-2874; Shamji MH, O., Agache I. EAAACI guidelines on environmental science in allergic diseases and asthma - Leveraging artificial intelligence and machine learning to develop a causality model in exposomics. *Allergy*. 2023;78(7):1742-1757; Agache I, et al. The Concept of One Health for Allergic Diseases and Asthma. *Allergy Asthma Immunol Res*. 2023;15(3):290-302; Kappen JH, Agache I, et al. Allergen Immunotherapy for Asthma. *J Allergy Clin Immunol Pract*. 2024;12(1):23-30; Agache I, et al. Immunotherapy: State of the art review of therapies and theratypes. *J Allergy Clin Immunol*. 2022;150(6):1279_1288 Agache I, et al. Multidimensional endotyping using nasal proteomics predicts molecular phenotypes in the asthmatic airways. *J Allergy Clin Immunol*. 2023;151(1):128_137. Agache I, et al. Climate change and global health: A call to more research and more action. *Allergy*. 2022 ;77(5):1389_1407 Agache I, et al. EAAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities. *Allergy*. 2022;77(6):1667_1684 Jutel M, ..., Agache I. COVID_19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals. EAAACI recommendations. *Allergy*. 2022;77(8):2313_2336 Agache I, et al. Molecular allergology approach to allergic asthma. *Mol Aspects Med*. 2022 Jun;85:101027 Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti_ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. *J Allergy Clin Immunol*. 2021;148(3):790_798 Agache I, et al. Advances and highlights in asthma in 2021. *Allergy*. 2021;76(11):3390_3407 Agache I, Akdis C, Akdis M, et al. EAAACI Biologicals Guidelines. Recommendations for severe asthma. *Allergy*. 2021;76(1):14_44 Agache I, Akdis C, Akdis M, et al. EAAACI Biologicals Guidelines. Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12_17 years old. *Allergy*. 2021 Jul 29. Agache I, Akdis CA, Akdis M, et al. EAAACI Biologicals Guidelines. dupilumab for children and adults with moderate_to_severe atopic dermatitis. *Allergy*. 2021;76(4):988_1009 Agache I. Severe asthma phenotypes and endotypes. *Semin Immunol*. 2019 Dec;46:101301. Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. *J Clin Invest*. 2019;129(4):1493_1503 Agache I, Lau S, Akdis CA, et al. EAAACI Guidelines on Allergen Immunotherapy: House dust mite_driven allergic asthma. *Allergy*. 2019;74(5):855_873 Breiteneder H, Peng YQ, Agache I, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. *Allergy*. 2020;75(12):3039_3068; Gao YD, Agache I, Akdis M, et al. The effect of allergy and asthma as a comorbidity on the susceptibility and outcomes of COVID_19. *Int Immunol*. 2021 Nov 12:dxab107. doi: 10.1093/intimm/dxab107. Epub ahead of print. PMID: 34788827 Sokolowska M, Lukasik ZM, Agache I, et al. Immunology of COVID_19: Mechanisms, clinical outcome, diagnostics, and perspectives. A report of the European Academy of Allergy and Clinical Immunology (EAAACI). *Allergy*. 2020;75(10):2445_2476 Vultaggio A, Agache I, Akdis CA, et al. Considerations on biologicals for patients with allergic disease in times of the COVID_19 pandemic: An EAAACI statement. *Allergy*. 2020;75(11):2764_2774; Pfaller B, Yepes_Nuñez JJ, Agache I, et al. Biologicals in atopic disease in pregnancy: an EAAACI position paper [published online ahead of print, 2020 Mar 18]. *Allergy*. 2020;10.1111/all.14282. doi:10.1111/all.14282 Agache I, Cojanu C, Laculiceanu A, Rogozea L. Genetics and epigenetics of allergy. *Curr Opin Allergy Clin Immunol*. 2020;20(3):223_232. Pfaar O, Agache I, de Blay F, et al. Perspectives in allergen immunotherapy: 2019 and beyond. *Allergy*. 2019;74 Suppl 108:3_25 Agache I, Cojanu C, Laculiceanu A, Rogozea L. Critical Points on the Use of Biologicals in Allergic Diseases and Asthma. *Allergy Asthma Immunol Res*. 2020;12(1):24_41 Agache I. Severe asthma phenotypes and endotypes. *Semin Immunol*. 2019;46:101301. Agache I, Lau S, Akdis CA, et al. EAAACI Guidelines on Allergen Immunotherapy: House dust mite_driven allergic asthma. *Allergy*. 2019;74(5):855_873 Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. *J Clin Invest*. 2019;130(4):1493_1503 Agache I, Miller R, Gern JE, et al. Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document. *Allergy*. 2019;74(3):449_463 Augé J, Vent J, Agache I, et al. EAAACI Position paper on

the standardization of nasal allergen challenges. Allergy. 2018;73(8):1597 - 1608 Agache I, Strasser DS, Pierlot GM, Farine H, Izuhara K, Akdis CA. Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma. J Allergy Clin Immunol. 2018;141(1):442 - 445 Agache I, Strasser DS, Klenk A, et al. Serum IL_5 and IL_13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics. Allergy. 2016;71(8):1192 - 1202. Agache I, Ciobanu C, Agache C, Anghel M. Increased serum IL_17 is an independent risk factor for severe asthma. Respir Med. 2010;104(8):1131 - 1137

Projects

PN_II_RU_TE_2014_4_2303: endotyping non_eosinophilic asthma; EAACI Guidelines for the use of Biologicals for allergic diseases and asthma; EAACI Guidelines on the Environmental Science for allergic diseases and asthma; EAACI Guidelines on Allergic Asthma; EAACI Guidelines for Allergen Immunotherapy; CHEST Guidelines on Severe Asthma; EAACI Guidelines on IgE mediated food allergy; ERS short guidelines for the use of as needed ICS/formoterol in mild asthma

Memberships

European Academy of Allergy and Clinical Immunology; European Respiratory Society; American Thoracic Society

Other Relevant Information

Past President (2017_2019) of the European Academy of Allergy and Clinical Immunology; Deputy Editor of Allergy journal; Associate Editor of Clinical and Translational Allergy journal